Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 1.00 |
| ▸ | FNTB | P49356 | 12/20 | 1.00 |
| ▸ | ICMT | O60725 | 1/20 | 0.86 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31002989 | 0.92 | ICMT (1.00) | FNTAFNTBICMTPGGT1B | |
| SCHEMBL16136627 | 0.92 | ICMT (1.00) | FNTAFNTBICMTPGGT1B | |
| SCHEMBL31741896 | 0.92 | FNTA (1.00) | FNTAFNTBICMTPGGT1B | |
| SCHEMBL17548810 | 0.92 | FNTA (1.00) | FNTAFNTBICMTPGGT1B | |
| SCHEMBL16112063 | 0.92 | FNTA (1.00) | FNTAFNTBICMTPGGT1B | |
| Trifluoroacetic Acid SCHEMBL16111192 | 0.88 | FNTA (0.91) | FNTAFNTBICMTPGGT1B | |
| SCHEMBL6776331 | 0.86 | FNTA (0.75) | FNTAFNTBICMT | |
| SCHEMBL6776327 | 0.86 | FNTA (0.75) | FNTAFNTBICMT | |
| SCHEMBL629257 | 0.82 | FNTA (0.69) | FNTAFNTBICMT | |
| SCHEMBL629256 | 0.82 | FNTA (0.69) | FNTAFNTBICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659812-A1 | DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION | Bumm, Thomas (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3166607-B1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | FNTA 3930/4885FNTB 2672/4885ICMT 3267/4885 |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | FNTA 3930/4885FNTB 2672/4885ICMT 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.